Method for prediction of risk of early microvascular complications of type i diabetes mellitus in children

FIELD: medicine.

SUBSTANCE: invention refers to medicine, namely to a method for the prediction of a risk of early microvascular complications in the children suffering from type 1 diabetes mellitus. The substance of the method consists in defining a duration of the diseases in years, the patient's age in years, a desquamated endothelial cell count, high-density lipoprotein cholesterol, total cholesterol, triglycerides, atherogenic index, glycohaemoglobin, average daily glycaemic level; making a linear regression analysis and calculating a risk ratio (R) of early microvascular complications in the children suffering from type 1 diabetes mellitus by formula. If the risk ratio is ≥1, the high risk of early microvascular complications during one year is predicted; the ratio < 1 shows the low risk of microvascular complications during one year.

EFFECT: using the declared method enables increasing the prediction accuracy of microvascular complications in the children with type 1 diabetes mellitus.

2 tbl, 2 ex

 

The invention relates to medicine, namely to endocrinology, and can be used to predict risk of early development of microvascular complications of diabetes type 1 (diabetic nephropathy, diabetic neuropathy) in children.

The number of diabetics on the planet more than 200 million people every 15-20 years, their number in the world doubles [1]. The disease is the leading cause of disability and mortality as a result of vascular complications. On the occurrence of microvascular complications is affected by several factors. Found that excess levels of glycated hemoglobin (HbA1c) at 1% over 8% during the three months increases the risk of developing microvascular complications by 40-50% [1]. In patients with newly diagnosed diabetes type 1 diabetes microvascular complications occur in 2%, whereas after 5 years from the onset of the disease in 47% of cases [2]. It should be noted that diabetic neuropathy often develops in males [3].

Known method for predicting diabetic nephropathy [4], based on the definition of risk factors with prognostic significance: diastolic blood pressure (Add) in mm Hg.CT., the initial value of the ratio of systolic velocities in the arc of the renal arteries (Vmax/Vmin), HbA1c, content trigly�of Eridu (TG) serum. The likelihood of developing diabetic nephropathy is determined by the formula:

D=-207,116×Vmax/Vmin-28,659×HbA1c-3,068×Add-20,079×TG.

When the value D is less than -844,07 predict the development of diabetic nephropathy in the course of the year.

The disadvantage of this method is the possibility of predicting the development of diabetic nephropathy, excluding the possibility of development of other microvascular complications of diabetes type 1.

The prototype was taken method of predicting the course of diabetes mellitus type 1 [5], based on the identification of risk factors after conducting a clinical examination of the patient, determination of blood biochemical parameters. Establish prognostic risk factors such as age, level of antioxidant activity, contents of total lipids, the concentration of diene conjugates, and predictive values of risk factors (F1, F2, F3, F4) determined by the formulas:

F1=-21,84+1,33×a1+0,59×a2+0,14×A3-0,94×a4;

F2=-49,72+2,04×a1+1,64×a2+0,44×a3-1,19×a4;

F3=-8,06+0,75×a1+1,61×a2-0,22×a3-0,26×a4;

F4=-6,82+0,64×a1-0,85×a2+0,30×a3-0,37×a4;

respectively, where a1 is the number of complete years, a2 - antioxidant activity (I.ed.), a3 - the content of total lipids (g/l), a4 is the concentration of diene conjugates (µmol/l).

When F1>F2, F3, F4or F2>F1, F3, F4predict a high risk of early development of microvascular complications and when F3>F1, F2, F4or F4>F1, F2, F3predict the development of microvascular complications, the appropriate duration of the disease.

The disadvantage of this method is the complexity of the calculation of the prognostic significance of risk factors on the one hand, and on the other, complex analysis are not all the factors contributing to the development of microvascular complications, which reduces the accuracy of prediction.

To simplify the method and improve the accuracy of forecasting of development of microvascular complications in children determine the level of triglycerides (mmol/l), desquamated endotheliocytes (YEC, ×104/l), glycated hemoglobin (%), mean daily blood glucose level (mmol/l), the concentration of cholesterol high density lipoproteins (HDL cholesterol, mmol/l), total cholesterol (total cholesterol, mmol/l), atherogenic coefficient (KA), disease duration (years) age of child (years). Then subjected to linear regression analysis to calculate the risk factor for the early development of microvascular complications of diabetes type 1 in children (P) by the formula:

P=R-A+D+G-O-L-T+K+H+E; where

R (constant) = 3,07

A = 0,14 × the patient's age (year)

D = 0,22 × duration of disease (year)

G = 0,066 × average blood glucose level (mmol/l)

O = 0,29 × total cholesterol (mmol/l)

p> L = 0,14 × cholesterol high density lipoprotein (mmol/l)

T = 2,27 × triglycerides (mmol/l)

K = 0,2 × atherogenic coefficient

H = 0,15 × the content of glycated hemoglobin (%)

E = 0,11 × content of desquamated endothelial cells (cells ×104/l)

When the value of the coefficient of ≥1 predict a high risk of development of microvascular complications of the disease during the year. If the ratio is less than 1, we predict a low risk of development of microvascular complications of the disease during the year.

The proposed method is as follows. Conduct clinical examination of the patient (define the duration of the disease, the age of the child). Determine blood biochemical parameters: the levels of triglycerides, cholesterol high density lipoprotein and total cholesterol (research carried out by enzymatic methods using based assays for the determination of lipoproteins of human serum), the content of desquamated endotheliocytes (determined by the method Hladovec in the modification of N. N. Petruseva [6; 7]), the content of glycated hemoglobin, mean daily blood glucose level (calculated on the basis of the glycemic profile of blood as the average of 5 measurements during the day). Based on the content triglycer�s in the blood count of KA:KA=(total cholesterol-HDL cholesterol)/HDL cholesterol.

To establish the prognostic value of risk factors, conduct a linear regression analysis. Then calculate the factor of risk of development of microvascular complications of diabetes type 1 in children (P) by the formula: P=R-A+D+G-O-L-T+K+H+E, where

R (constant) = 3,07

A = 0,14 × the patient's age (year)

D = 0,22 × duration of disease (year)

G = 0,066 × average blood glucose level (mmol/l)

O = 0,29 × total cholesterol (mmol/l)

L = 0,14 × cholesterol high density lipoprotein (mmol/l)

T = 2,27 × triglycerides (mmol/l)

K = 0,2 × atherogenic coefficient

H = 0,15 × the content of glycated hemoglobin (%)

E = 0,11 × content of desquamated endothelial cells (cells ×104/l)

If the result of the calculation obtained number ≥1, we predict a high risk of development of microvascular complications of the disease during the year. If the calculation results in the number<1, we predict a low risk of development of microvascular complications of the disease during the year. The risk factors included in the analysis on the basis of their contribution to the formation of complications (table 1), determined by analysis of variance.

The proposed method is illustrated by the following examples.

Example 1: Patient K. was Admitted to the Department of endocrinology at planewholesale with a diagnosis of Diabetes mellitus type 1, the phase of decompensation without ketosis, moderate, uncomplicated, disease duration of 6 years. Boy, 11 years 2 months old. the duration of diabetes type 1 diabetes 6 years 3 months. No complaints. The average blood glucose level amounted of 12.53 mmol/l, HbA1c levels at 9.1 percent, the concentration of TG - 1.54 mmol/l, total cholesterol - to 4.68 mmol/l, HDL cholesterol - 2.99 mmol/l, KA is equal 0,565, the number of desquamated endotheliocytes was 13×104/L. When instrumental and laboratory examination of microvascular complications of diabetes type 1 not found.

We expect the risk of developing microvascular complications by the formula:

P=R-A+D+G-O-L-T+K+H+E=3,07-0,14×11,16+0,22×6,24+0,066×12,53-0,29×4,68-0,14×2,99-2,27×1,54+0,2×0,565+0,15×9,1+0,11×13=1,35 1,35>1

The patient belongs to the group with high risk of development of microvascular complications over a year. The boy received conventional therapy. When re-planned hospitalization (10 months) on the basis of electromyography data set the development of diabetic polyneuropathy.

Example 2: a Boy, 10 years 2 months old. the disease duration was 2 years. Received for planned hospitalization with a diagnosis of diabetes mellitus type 1, phase subcompensation, moderate, uncomplicated, disease duration 2 years. No complaints. The average blood glucose level amounted to 6.00 mmol/l, HbA1c levels of 5.5%, the concentration�Oia TG - 1,50 mmol/l, cholesterol - 4,31 mmol/l, HDL cholesterol - 0,44 mmol/l, KA is equal 8,796, the number of YEC was 4×104/L. When instrumental and laboratory examination of microvascular complications of diabetes type 1 was not detected. We expect the risk of developing microvascular complications by the formula:

P=R-A+D+G-O-L-T+K+H+E=3,07-0,14×10,16+0,22×2+0,066×6,00-0,29×4,31-0,14×0,44-2,27×1,50+0,2×8,796+0,15×5,5+0,11×4=0,8 0,8<1

The patient belongs to the group with low risk of premature development of microvascular complications. On the background of traditional therapy with repeated planned hospitalization (14 months) is not revealed microvascular complications of diabetes of the first type.

Example 3: Girl, 8 years 4 months old. the disease duration was 2 years and 11 months. Received for planned hospitalization with a diagnosis of diabetes mellitus type 1, phase subcompensation, moderate, uncomplicated, disease duration 2 years 11 months.No complaints. The average blood glucose level amounted to 8.43 mg/l, the content of HbA1c is 6.2%, the concentration of TG - 1.5 mmol/l, cholesterol - 4,90 mmol/l, HDL cholesterol was 0.63 mmol/l, KA is equal 6,78, the number of YEC was 16×104/L. When instrumental and laboratory examination of microvascular complications of diabetes type 1 was not detected. We expect the risk of developing microvascular complications by the formula:

P=R-A+D+G-O-L-T+K+H+E=3,07-0,14×8,4+0,22×2,8+0,066×8,43-0,29×4,90-0,14×0,63-2,27×1,5+0,2×6,78+0,15×,2+0,11×16=2,19 2,19> 1

The patient belongs to the group with a high risk of early development of microvascular complications. Given the high risk of complications, the patient received conventional treatment in combination courses of the drug α-lipoic acid (Berlition) for preventive therapy. When re-planned hospitalization (12 months) revealed microalbuminuria (once), microvascular complications of diabetes mellitus type 1 is not installed.

Evaluation of the effectiveness of the proposed method of predicting the development of microvascular complications of diabetes type 1 in children was conducted on a control sample of 20 children with diabetes mellitus type 1. The accuracy of forecasting of development of microvascular complications of diabetes type 1 in children was 95% (table 2).

The method is easily reproducible and allows to ensure the accuracy of predicting the risk of early development of microvascular complications in children with diabetes mellitus type 1.

The list of references

1. Dedov I. I. Russian consensus on treatment of diabetes mellitus in children and adolescents / by I. I. Dedov, V. A. Peterkova, T. L. Kuraeva // Farmateka. - 2010. - No. 3. - Pp. 7-14.

2. Pankratova M. S. Efficacy of the drug Digamma in diabetic polyneuropathy // Questions of medical practice. - 2010. - No. 11 [XI]. - C. 62-65.

3. Galstyan G. R. Chronic complications of diabetes mellitus: etiopathogenesis, clinical picture, treatment [Electronic resource] / G. R. Galstyan. - Endocrinological scientific center, RAMS, Moscow, 2009. - Access mode: www.rmj.ru (13 Oct.2010).

4. Pat. No. 2200328, Russian Federation, IPC 7 G01N 33/72, G01N 33/92, A61B 5/02. A method of predicting diabetic nephropathy / O. A. Danchenko, S. V. Naryshkin, V. P. Kolosov, applicant and patentee of the Amur state medical Academy. - No. 2001128559/14; Appl. 22.10.01; publ. 10.03.03.

5. Pat. No. 2320272, Russian Federation, IPC A61B 10/00. A method of predicting the course of diabetes mellitus type 1 / Etc Bardymov, Dedov I. I., L. I. Kolesnikov, S. V. Tyumentsev, V. A. Petrova, I. M. Mikhalevich; applicant and patentee Etc. Bardymov. - No. 2006124937/14; Appl. 11.07.06; publ. 27.03.08.

6. Petrishchev N. N. Diagnostic value of the determination of desquamated endothelial cells in the blood / N. N. Petrishchev, O. Berkovich, T. D. Vlasov // Clinical laboratory diagnostics. - 2001. - No. 1. - 50-52.

7. Hladovec J. Circulating endothelial cells as a sign of vessel wall lesions / J. Hladovec / TPhysiol. Bohemoslov. - 1978. - Vol. 27, 2. - P. 140-144.

A method of predicting the risk of early development of microvascular complications in children with diabetes mellitus type 1, which includes clinical examination of the patient, determination of blood biochemical parameters, characterized in that determine the duration of Zabol�tion, the age of the patient, the content of desquamated endothelial cells, cholesterol high density lipoprotein, total cholesterol, triglycerides, atherogenic ratio, glycated hemoglobin levels, mean daily blood glucose levels, conduct a linear regression analysis to calculate the risk factor for the early development of microvascular complications (P) by the formula: P=R-A+D+G-O-L-T+K+H+E; where
R (constant) = 3,07
A = 0,14 × the patient's age, year
D = 0,22 × duration of disease, year
G = 0,066 × average blood glucose level, mmol/l
O = 0,29 × total cholesterol, mmol/l
L = 0,14 × cholesterol high density lipoprotein, mmol/l
T = 2,27 × triglycerides, mmol/l
K = 0,2 × atherogenic coefficient
H = 0,15 × the content of glycated hemoglobin, %
E = 0,11 × content of desquamated endothelial cells, ×104/l and when the value of the coefficient of ≥1 predict a high risk of development of microvascular complications of the disease during the year, and a value of the coefficient <1 predict a low risk of development of microvascular complications of the disease during the year.



 

Same patents:

FIELD: medicine.

SUBSTANCE: group of inventions refers to medicine and can be used for patient's status monitoring. A method for setting a time-varying physiological parameter warning signal involves patient's controlled parameter monitoring, comparing the controlled parameter to an initial cut-off criterion, varying the cut-off criterion temporarily by a cut-off criterion of deterioration after the therapy, and then after a certain period of time, by the cut-off criterion after the administration. The time allowed involves comparing the controlled parameter to the cut-off criterion of deterioration, and after the time allowed - to the cut-off criterion after the administration. The warning signal is initiated in response to the controlled parameter of one or more initial cut-off criteria, the cut-off criterion of deterioration and the cut-off criterion after the administration. The group of inventions also refers to a machine-readable carrier with software for implementing the method and to a system for user warning on the controlled parameter variation.

EFFECT: group of inventions provides higher accuracy and rate of assessing the patient's status according to the conducted therapy.

15 cl, 6 dwg

FIELD: medicine.

SUBSTANCE: invention can be used for the purpose of the early prediction of cystic periventricular leukomalacia (PVL) in the newborns with very low (VLBW) or extremely low body weight (ELBW). Substance of the method: the newborns with VLBW and ELBW on the 3rd-7th day of life are examined to assess the perinatal medical history, namely the presence of chorioamnionitis and amniotic fluid nature, 5th minute Apgar score, the absence of prolonged artificial pulmonary ventilation, a severity of respiratory distress syndrome, the presence of pneumonia, sepsis, convulsive disorder, anaemia, laboratory signs of the systemic inflammatory reaction, average values of carbon dioxide, anionic bicarbonate and base deficiency in capillary blood, interleukine-6 and receptor interleukine-1 antagonist in venous blood serum. Each sign is assigned with a prognostic coefficient (PC). That is followed by determining total PC, and it is expected cystic PVL that is decided for if total PC is at least (+)9.5, whereas no cystic PVL is expected if total PC is (-)9.5 or less.

EFFECT: invention provides the early (for the first 7 days of life) prediction of cystic periventricular leukomalacia in the most susceptible category of patients that are children with very low and extremely low birth weight.

6 tbl, 5 ex

FIELD: medicine.

SUBSTANCE: interferon is measured in plasmocytoid dendrite cells at week 12 of the treatment. Its gain in adults and children twenty times as much as compared to the pre-treatment initial level, or 2.6×102 times as much in adults, and 1.2×102 as much as compared to the normal values, the stable positive antiviral treatment response is predicted.

EFFECT: method enables providing the more accurate prediction for selecting the optimum therapeutic approach in each patient.

4 ex

FIELD: medicine.

SUBSTANCE: invention represents a method for assessing the mucosal immunity state of open cavities accompanying the prediction of the clinical course of infectious-inflammatory processes, characterised by the fact that having a pathogenetic factor established, degrees of microbiocoenosis disturbances of a specific biotope are recorded with the use of a complex of methods for estimating colonisation resistance factors, namely normal microflora, opportunistic microflora, immunoglobulins G, M, A, secretory immunoglobulin A and sc component; the mucosal immunity state is assessed according to the degree of microbiocoenosis disturbance, and the favourable outcome implying agent eradication or chronisation with agent persistence is predicted. The invention also refers to a method for correcting the infectious-inflammatory processes with the Kipferon® immunomodulator added.

EFFECT: increasing the prediction accuracy of the clinical course of the disease, extending the range of the method for correcting the infectious-inflammatory processes.

2 cl, 3 ex, 6 tbl, 1 dwg

FIELD: medicine.

SUBSTANCE: content of calcium and protein in oral liquid is determined before and after physical load, as well as a day after physical load. Recovery of content of calcium ions and protein in oral liquid after physical load to initial values is considered to be a criterion of total recovery of athlete's-volleyball player's organism, with evaluating time interval, required for said process.

EFFECT: invention makes it possible to determine reserve abilities of organism and its adaptability in athletes-volleyball players to physical load.

2 dwg, 4 tbl

FIELD: medicine.

SUBSTANCE: invention relates to the field of veterinary and can be used to diagnose the presence of a pathological effect of iron dextran on the piglets' liver. The essence of the method consists in carrying out the morphological systemic step-by-step analysis of histological liver cuts with the description of its histological structure, measurement of the average quantity of binucleate hepatocytes, apoptotic bodies and cells of the mononuclear-macrophage system. If the complex of pathognomonic morphological changes, including the presence of blood filling of sinus capillaries, oedema of the Disse's space; swelling of the vascular endothelium, granular dystrophy of hepatocytes, increase of the average quantity of cells of the mononuclear-macrophage system, including haemosiderophages by two times and more, as well as an increase of the quantity of binucleate hepatocytes and apoptotic bodies by 2 times and more, the effect of iron dextran on the piglets' liver condition is considered to be pathological.

EFFECT: invention provides an increased accuracy of the post-mortem diagnostics of the presence of a pathological effect of iron dextran on the piglets' liver.

1 tbl

FIELD: medicine.

SUBSTANCE: after thymomegalia has been excluded, tissue specimens of three-day-old mature newborns are studied to evaluate areas of inflammation changes in points in the placental umbilical cord (A), in the foetal placenta (B), in the maternal placenta (C), in extraplacental membranes (D); then thymomegalia is predicted by a discriminant equation: DE=-0.350×A-1.176×B-1.690×C-1.203×D, wherein DE is a discriminator function with a threshold equal to - 15.00. If DE is equal to or more than the threshold, the absence of thymomegalia is predicted; if D is less than the threshold, thymomegalia is predicted, whereas the score is taken at: (A) - 1 point - no inflammation, 2 points - amnionitis, 3 points - leukocytic infiltration in the Wharton's jelly, 4 points - phlebitis, 5 points - arteriitis, 6 points - a combination of two or more areas of inflammation: in blood vessels or in vessels and in the Wharton's jelly, (B) - 1 point - no inflammation, 2 points - chorioamnionitis, 3 points - villusitis, 4 points - vasculitis, 5 points - intervillesitis, 6 points - a combination of two or more areas of inflammation, (C) - 1 point - no inflammation, 2 points - villusitis, 3 points - vasculitis, 4 points - intervillesitis, 5 points - deciduitis, 6 points - a combination of two or more areas of inflammation, (D) - 1 point - no inflammation, 2 points - amnionitis, 3 points - chorioamnionitis, 4 points - deciduitis, 5 points - choriodeciduitis, 6 points - a combination of two or more areas of inflammation.

EFFECT: enabling the prediction of thymomegalia in the three-month-old mature newborns suffered prenatal influenza B complicated by placentitis.

2 ex

FIELD: veterinary medicine.

SUBSTANCE: method consists in determining in the scales of concentration of Mn and/or Cu by the method of atomic-emission spectrometry. The regression equation is calculated, and on the content of Mn and/or Cu in the scales a copper concentration is determined.

EFFECT: method is accurate, atraumatic and non-invasive, simple and easy to use.

3 tbl, 1 ex

FIELD: medicine.

SUBSTANCE: after the ablation of the spleen, its weight is determined, the average area of a marginal zone of the spleen in histological cuts with coloration with hematoxylin and eosin is measured morphometrically. The obtained values are used to calculate the weight of the marginal zone and, if its values are ≤1.9 g, a favourable prognosis for the course of aplastic anaemia is made, if its value is >1.9 g, an unfavourable course of the disease is predicted.

EFFECT: prognosis of the aplastic anaemia course after splenectomy independent on the severity of the disease with the possibility to approach therapeutic treatment in a differential way.

2 ex

FIELD: medicine.

SUBSTANCE: blood serum fasting adiponectin and leptin concentrations are measured in the morning in the female adolescents diagnosed with oligomenorrhea and obesity. An adiponectin/leptin ratio is derived. If the ratio is 0.6 or less, insulin resistance is stated in the female patients suffering oligomenorrhea and obesity, and the therapy is started with prescribing metformin, an insulin sensitiser. The adiponectin/leptin ratio of more than 0.3 enables diagnosing the absence of insulin resistance and prescribing hormonal contraceptives with drospirenone.

EFFECT: effective treatment of oligomenorrhea and obesity by selecting the adequate treatment taking into account the carbohydrate metabolism status.

1 tbl, 3 ex

FIELD: medicine, psychiatry.

SUBSTANCE: one should isolate DNA out of lymphocytes of peripheral venous blood, then due to the method of polymerase chain reaction of DNA synthesis one should amplify the fragments of hSERT locus of serotonin carrier gene and at detecting genotype 12/10 one should predict the risk for the development of hallucino-delirious forms of psychoses of cerebro-atherosclerotic genesis.

EFFECT: more objective prediction of disease development.

3 ex

FIELD: medicine, urology.

SUBSTANCE: one should conduct subcutaneous prevocational tuberculin test and, additionally, both before the test and 48 h later it is necessary to perform the mapping of prostatic vessels and at decreased values of hemodynamics one should diagnose tuberculosis. The information obtained should be documented due to printing dopplerograms.

EFFECT: more reliable and objective information.

1 ex, 1 tbl

FIELD: molecular biology.

SUBSTANCE: the suggested innovation deals with the fact that nucleic acids should be isolated directly out of the sample without pipetting stage but with the help of interconnected reservoirs being prepared beforehand. The above-mentioned vessels should be applied either separately or being interconnected according to standard microtitrating format. The sample should be mixed with a lyzing buffer and nucleic acids are bound with matrix in closed system including, at least, two interconnected reservoirs. Forced movement of sample's mixture and buffer back and forth from one reservoir into another one for several times through narrow passage provides their thorough intermixing. The method provides quick and safe isolation of nucleic acids.

EFFECT: higher efficiency.

44 cl, 4 dwg, 1 ex

FIELD: medicine, phthisiology, microbiology.

SUBSTANCE: diagnostic material is poured preliminary with chlorohexidine bigluconium solution, homogenized, kept at room temperature for 10-12 h and centrifuged. Precipitate is poured with Shkolnikova's liquid medium, incubated at 37oC for 3 days, supernatant part of Shkolnokova's medium is removed, fresh Shkolnikova's medium is added, and precipitate is stirred and inoculated on the dense cellular egg media. Sensitivity of the strain is determined in 3 weeks by the presence of growth in the control tube only. Invention provides enhancing precision and reducing time for assay. Invention can be used in assay for medicinal sensitivity of tuberculosis mycobacterium.

EFFECT: improved assay method.

3 ex

FIELD: medicine, biotechnology, pharmacy.

SUBSTANCE: invention relates to agents used for treatment of pathological states associated with disorder of synthesis of neuromediating substances. Method involves the development of pharmaceutical composition and a method for it preparing. Pharmaceutical composition represents subcellular synaptosomal fractions: synaptic membranes, "light" synaptosomes and "heavy" synaptosomes prepared from gray matter of cerebral hemispheres from experimental animals based on the goal-seeking modification of humoral mediators of nerve endings transformed to synaptosomes in development and regression of malignant processes. The composition provides inhibiting the growth of tumor cells, to elevate span-life of patients with ascite Ehrlich's sarcoma, breast adenocarcinoma Ca-755, Wolker's carcinosarcoma-256.

EFFECT: valuable medicinal and anti-tumor properties of composition.

12 cl, 3 tbl, 3 ex

FIELD: medicine.

SUBSTANCE: method involves carrying out microscopic examination of blood serum samples taken from femoral vein and cubital vein. Femoral vein sample is taken on injured side. The examination is carried out before and after treatment. The blood serum samples are placed on fat-free glass slide in the amount of 0.01-0.02 ml as drops, dried at 18-30°C for 18-24 h. The set of pathological symptoms becoming larger or not changed after the treatment in comparison to sample taken before treatment, and morphological picture of samples under comparison taken from the cubital vein showing no changes or being changed to worse, the treatment is considered to be effective.

EFFECT: enabled medicamentous treatment evaluation in course of treatment to allow the treatment mode to be changed in due time; avoided surgical intervention (amputation); retained active life-style of aged patients.

4 dwg

FIELD: medicine, clinical toxicology.

SUBSTANCE: at patient's hospitalization one should gather the data of clinical and laboratory values: on the type of chemical substance, patient's age, data of clinical survey and laboratory values: body temperature, the presence or absence of dysphonia, oliguria being below 30 ml/h, hemoglobinuria, erythrocytic hemolysis, exotoxic shock, glucose level in blood, fibrinogen and creatinine concentration in blood serum, general bilirubin, prothrombin index (PTI), Ph-plasma, the state of blood clotting system. The state of every sign should be evaluated in points to be then summed up and at exceeding the sum of points being above "+20" one should predict unfavorable result. At the sum of "-13" prediction should be stated upon as favorable and at "-13" up to "+20" - prediction is considered to be doubtful.

EFFECT: higher accuracy of prediction.

2 ex, 3 tbl

FIELD: medicine, juvenile clinical nephrology.

SUBSTANCE: disease duration in case of obstructive pyelonephritis should be detected by two ways: either by detecting the value of NADPH-diaphorase activity, as the marker of nitroxide synthase activity in different renal department and comparing it to established norm, or by detecting clinico-laboratory values, such as: hemoglobin, leukocytes, eosinophils, urea, beta-lipoproteides, lymphocytes, neutrophils, the level of glomerular filtration, that of canalicular reabsorption, urinary specific weight, daily excretion of oxalates, arterial pressure, and estimating their deviation against average statistical values by taking into account a child's age.

EFFECT: higher efficiency of detection.

7 dwg, 1 ex, 6 tbl

FIELD: medicine, urology.

SUBSTANCE: the present innovation deals with differential diagnostics of prostatic cancer and other prostatic diseases at the stage of primary inspection. The method includes the detection of PCA and calculation of probability coefficient for prostatic cancer (PCC) by the following formula: where e - the foundation of natural logarithm (e=2.718…), PCA - the level of total blood PCA in ng/ml, V - patient's age in years. At PCC value being above 0.2 one should diagnose prostatic cancer and to establish final diagnosis one should perform polyfocal prostatic biopsy. The method enables to increase accuracy of diagnostics at decreased number of unjustified prostatic biopsies.

EFFECT: higher efficiency of diagnostics.

2 ex

FIELD: medicine, biology.

SUBSTANCE: invention relates to nutrient medium used for accumulation of cells for the following cytological and/or immunocytochemical analysis carrying out. Invention relates to medium containing salts NaCl, KCl, anhydrous CaCl2, MgSO4 x 6 H2O, MgCl2 x 6 H2O, Na2HPO4 x 2 H2O, KHPO4, NaHCO3, and also glucose and Henx's solution, 10% albumin solution and polyglucin taken in the ratio 1:1:1. Invention provides enhancing the preservation of cells.

EFFECT: improved an valuable properties of nutrient medium.

3 ex

Up!